

Brian F. Faulkner

A PROFESSIONAL LAW CORPORATION

27127 CALLE ARROYO, SUITE 1923 . SAN JUAN CAPISTRANO, CALIFORNIA 92675
T: 949.240.1361 . F: 949.240.1362 . C: 714.608.2125
E: BRIFFAULK@AOL.COM

May 3, 2016

OTC Markets Group Inc.
304 Hudson Street, 2nd Floor
New York, New York 10013

Re: Solos Endoscopy, Inc. (SNDY)

Dear Sir/Madame:

I have been retained by Solos Endoscopy, Inc., a Nevada corporation ("Company"), for the purpose of rendering this letter to OTC Markets Group Inc. ("OTC Markets") with respect to the information publicly disclosed by the Company and published in the OTC Disclosure & News Service. OTC Markets is entitled to rely on this letter in determining whether the Company has made adequate current information publicly available within the meaning of Rule 144(c)(2) under the Securities Act of 1933, as amended ("Securities Act").

I hereby represent that I am a U.S. resident. I am licensed to practice law in the State of California and I am permitted to practice before the U.S. Securities and Exchange Commission ("SEC"); I have not been prohibited from practice before them. As such, I am permitted to opine on the federal laws of the United States. I have been retained by the Company for the purpose of rendering this letter and related matters solely for the purpose of reviewing the current information supplied by the Company; as such, I was not involved in the drafting of such current information.

In connection with rendering this opinion, I have investigated such corporate records and other documents, and such questions of law as counsel considered necessary or appropriate for purposes of rendering this letter. In examining the documents, I have assumed the genuineness of signatures (both manual and conformed), the authenticity of documents submitted as originals, the conformity with originals of all documents furnished as copies and the correctness of facts set forth in such documents.

In addition to the previously reviewed documents as referenced in my Attorney Letters dated April 26, 2012, May 24, 2012, September 10, 2012, December 14, 2012, April 22, 2013, April 29, 2014, and April 30, 2015, I have also reviewed the following documents ("Information") in connection with the preparation of this letter:

<u>Document</u>	<u>Date of Posting on OTC Disclosure & News Service</u>
Annual Financial Statements – Years Ended December 31, 2015 and 2014	April 26, 2016
Annual Disclosure Statement – Year Ended December 31, 2015	April 26, 2016

Based on the examination and inquiry set forth above, I am of opinion that the Information: (a) constitutes “adequate current public information” concerning the common stock of the Company quoted on the OTC Markets (“Securities”) and the Company itself, and “is available” within the meaning of Rule 144(c)(2) under the Securities Act; (b) includes all of the information that a broker-dealer would be required to obtain from the Company to publish a quotation for the Securities under Rule 15c2-11 under the Securities Exchange Act of 1934, as amended; (c) complies as to form with the OTC Markets’ Guidelines for Providing Adequate Current Information, which are located on the Internet at www.otcm Markets.com; and (d) has been posted through the OTC Disclosure & News Service.

The financial statements are not audited and were prepared with the assistance of Fred V. Schiemann, C.P.A., one of the Company’s directors. These statements were then reviewed by management prior to filing. The primary officer reviewing and approving the Company’s financial statements is Robert Segersten, the Company’s President and Chief Executive Officer. Mr. Segersten has a Bachelor of Science degree from Bates College and Juris Doctor degree from Boston University, and has had many years’ experience with public companies and their financial statements.

The Company’s transfer agent is Pacific Stock Transfer Company. (“Transfer Agent”). The Transfer Agent is registered with the SEC. I have confirmed the number of outstanding shares as set forth in this Information by reviewing the records of the Company and the Transfer Agent.

I have previously personally met with management and a majority of the directors of the Company, have reviewed the Information published by the Company through OTC Disclosure & News Service, and have discussed the Information with management and a majority of the directors of the Company.

To my best knowledge, after inquiry of management and the directors of the Company, neither the Company, its officers and directors, any holder of 5% or more of the securities of the Company, nor this counsel is currently under investigation by any federal or state regulatory authority for any violation of federal or states securities laws.

This letter is being delivered to OTC Markets for its sole use and benefit and is not to be used, circulated, quoted or otherwise referred to or relied upon for any other purpose without express written consent, except that OTC Markets has full and complete permission and rights to publish this letter through the OTC Disclosure & News Service for viewing by the public and regulators.

OTC Markets Group Inc.
May 3, 2016
Page 3

It is understood that I express no opinion as to the applicability to or compliance with any state securities laws and regulations. In addition, this letter is given as of the date set forth above and is restricted to the stated facts and circumstances presented to me and described herein, and that any other or different facts and circumstances might require a different letter by me. I assume no, and hereby disclaim any, obligation to update or supplement this letter to reflect any facts or circumstances that may hereafter come to my attention or any changes in laws that may hereafter occur.

Sincerely,

A handwritten signature in black ink, appearing to read "B. F. Faulkner", with a long horizontal flourish extending to the right.

Brian F. Faulkner